Superiority of the DNA Amplification Assay for the Diagnosis of C. difficile Infection: A Clinical Comparison of Fecal Tests
- 289 Downloads
Clostridium difficile infection (CDI) is a major infectious concern, accounting for substantial morbidity and resource utilization. Advances in microbiological and molecular techniques have resulted in an increasing number of testing options for CDI. A glutamate dehydrogenase (GDH) enzyme immunoassay (EIA) and a DNA amplification (DNA-A) test for the diagnosis of CDI have recently become commercially available.
The aim of this prospective study was to compare the test performance characteristics of the traditional diagnostic modality for CDI diagnosis, the toxin A/B (TOX) EIA, with those of the GDH EIA and DNA-A test, utilizing enriched toxigenic culture (TGC) as the gold standard. Clinical variables predictive of CDI were also studied.
Participants fulfilled one or more criteria placing them at increased risk for CDI. Each stool sample was tested by each of the methods mentioned above. Clinical data parameters were collected via a 12-month review of the electronic medical record prior to the index date of the first stool test.
A total of 272 stool samples from 144 admissions of 139 patients were evaluated for CDI. The sensitivity and positive predictive value (PPV) of the TOX EIA were 86.1 and 58.4 %, respectively, whereas the sensitivity and PPV of the GDH EIA and DNA-A test were 100 %. 1.8 % of the GDH tests yielded inconclusive results. Using TGC as the gold standard, nosocomial exposure with emphasis on nursing home residence, history of previous CDI, and female gender were predictive of CDI.
Test performance characteristics of the DNA-A test and GDH EIA were superior to those of the traditional TOX EIA. The GDH test is limited by inconclusive test results and requires a multi-step diagnostic algorithm. Therefore, the DNA-A test should be implemented as the diagnostic method of choice for CDI. CDI clinical predictors are important for diagnostic decision-making.
KeywordsClostridium difficile Diagnosis Immunoenzyme assays DNA amplification
- 3.Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors, and management. Nat Rev Gastroenterol Hepatol. 2011;8:17–26.Google Scholar
- 4.U.S. Department of Health and Human Services. HCUPnet [online]. Available at: http://hcupnet.ahrq.gov/. Accessed 2010.
- 6.Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea, and colitis. World J Gastroenterol. 2009;15:1554–1580.Google Scholar
- 7.Carroll KC, Bartlett JG. Biology of Clostridium difficile: implications for epidemiology and diagnosis. Ann Rev Microbiol. 2011;65:501–521.Google Scholar
- 9.Doing KM, Hintz MS, Keefe C, et al. Reevaluation of the Premier Clostridium difficile toxin A and B immunoassay with comparison to glutamate dehydrogenase common antigen testing evaluation Bartels cytotoxin and ProdeseProGastro Cd polymerase chain reaction as confirmatory procedures. Diagn Microbiol Infect Dis. 2010;66:129–134.PubMedCrossRefGoogle Scholar
- 13.Stamper PD, Alcabasa R, Aird D, et al. Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples. J Clin Microbiol. 2009;47:373–378.PubMedCrossRefGoogle Scholar
- 17.Eastwood K, Else P, Charlett A, et al. Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol. 2009;47:3211–3217.PubMedCrossRefGoogle Scholar
- 19.Meridian Bioscience. Meridian illumigene assay package insert and product information. Available at: http://www.meridianbioscience.com/diagnostic-products/c-difficile/illumigene-molecular-diagnostic-system/illumigene-c-difficile. 2011. Accessed 19 Oct 2011.
- 21.Mellow M, Kanatzar A, Brandt L, et al. Long term follow-up of colonoscopic fecal microbiota transplant (FMT) for recurrent C. difficile infection (RCDI). Podium Presentation at American College of Gastroenterology 2011 National Meeting. Washington, DC.Google Scholar